Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 12, 2022New England Journal of MedicineOpen Access

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2022 study studied this question.

synapsesocial.com/papers/6a7ff9d7826e8e37b93d3553https://doi.org/10.1056/nejmoa2115481
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study2021 · 1,394 citations
  2. 2Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster2021 · 90 citations
  3. 3Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 20212021 · 330 citations
  4. 4High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients2021 · 105 citations
  5. 5Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study2021 · 614 citations